New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly- ...

Synendos Therapeutics appoints Dr. George Garibaldi to move phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Wednesday, July 16, 2025, 15:45 Hrs [IS ...

Treatment with memantine in a small cohort of individuals with post-traumatic headache led to fewer average headache days per ...

Scientists challenging conventional beliefs around the genetic risk factors for Alzheimer’s have discovered a genetic link ...

Quest Diagnostics (DGX) is a strong buy with growth potential, solid margins, and dividend increases. Discover the full ...

Overview of Autologous Cell Therapy Product MarketGlobal Cell Therapy Market is valued at USD 10.1 Billion in 2025 and is ...

Synendos Therapeutics (“Synendos”), the clinical-stage biotechnology company developing breakthrough therapies for ...

As Alzheimer's disease progresses beyond the early stages, the behavior changes and emotional impacts of the disease can be ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

The value of a recent biochemical discovery can be seen in the case of an 8-year-old boy, who was playing typical sports in ...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect product line for assessing symptomatic ...